Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes

QR Code

Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes

Jonathan K ReynoldsWashington State University, College of Pharmacy, Pullman, WA, USAAbstract: JanumetTM, a fixed dose combination of sitagliptin/metformin HCL manufactured by Merck Pharmaceuticals, has received US Food and Drug Administration approval for treatment of patients with type 2 diabetes,...

Description complète

Enregistré dans:

Détails bibliographiques
Auteur principal:	Jonathan K Reynolds
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2009
Sujets:	Specialties of internal medicine RC581-951
Accès en ligne:	https://doaj.org/article/c03116aca28d4503b4a56a3c00a08e98
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Clinical utility of fixed combinations of sitagliptin&ndash;metformin in treatment of type 2 diabetes
par: Karen Barnard, et autres
Publié: (2010)

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
par: Green J, et autres
Publié: (2010)

Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination
par: Fleming JW, et autres
Publié: (2015)

Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
par: Maffioli P, et autres
Publié: (2011)

Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
par: Shannon A Miller, et autres
Publié: (2009)

Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
par: Robert G Moses
Publié: (2010)

Fixed combination of repaglinide and metformin in the management of type 2 diabetes
par: Robert Moses
Publié: (2009)

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
par: Holl, et autres
Publié: (2014)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
par: Bo Ahr&eacute;n
Publié: (2010)

Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus
par: Omoto S, et autres
Publié: (2015)

Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
par: Moses R
Publié: (2010)

Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated
par: Irons BK, et autres
Publié: (2014)

Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated [Corrigendum]
par: Irons BK, et autres
Publié: (2017)

Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes
par: Stolar MW, et autres
Publié: (2013)

Long-term (52&ndash;78 weeks) treatment with colesevelam HCl added to metformin therapy in type 2 diabetes mellitus patients
par: Bays HE
Publié: (2012)

Pioglitazone improves the cardio-ankle vascular index in patients with type 2 diabetes mellitus treated with metformin
par: Ohira M, et autres
Publié: (2014)

Comparison Between Pioglitazone/Metformin Combination Therapy and Sitagliptin/Metformin Combination Therapy on the Efficacy in Chinese Type 2 Diabetic Adults Insufficiently Controlled with Metformin: Study Protocol of an Open-Label, Multicenter, Non-Inferiority Parallel-Group Randomized Controlled Trial
par: Zhang F, et autres
Publié: (2021)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
par: Ahren B
Publié: (2010)

Risk management in the treatment of type 2 diabetes with pioglitazone
par: Giuseppe Derosa, et autres
Publié: (2009)

Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
par: Rigato M, et autres
Publié: (2014)

Insulin detemir for the treatment of obese patients with type 2 diabetes
par: Hollander PA
Publié: (2012)

Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins
par: Di Pierro F, et autres
Publié: (2015)

Combination of Metformin and Exercise in Management of Metabolic Abnormalities Observed in Type 2 Diabetes Mellitus
par: Jevtovic F
Publié: (2021)

Treatment of type 2 diabetes in chronic kidney disease: a case for linagliptin in the treatment of diabetes in severe renal impairment
par: Scott D
Publié: (2013)

Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence
par: Sosale A, et autres
Publié: (2015)

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
par: Kishimoto M
Publié: (2013)

Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability
par: Nishio S, et autres
Publié: (2015)

Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
par: Stanley S Schwartz
Publié: (2010)

Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin
par: Schwartz SS, et autres
Publié: (2016)

Metformin Treatment: A Potential Cause of Megaloblastic Anemia in Patients with Type 2 Diabetes Mellitus
par: Albai O, et autres
Publié: (2020)

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
par: Baptist Gallwitz
Publié: (2010)

Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
par: Petersen AB, et autres
Publié: (2013)

Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus
par: Konya H, et autres
Publié: (2013)

Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
par: Paul Valensi
Publié: (2009)

Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes
par: Peggy Soule Odegard, et autres
Publié: (2009)

Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes
par: Mann KV, et autres
Publié: (2014)

Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes
par: Hoimark L, et autres
Publié: (2012)

Saxagliptin for type 2 diabetes
par: Antonio R Chacra, et autres
Publié: (2010)

SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
par: Seufert J
Publié: (2015)

An observational study of acarbose treatment in patients with type 2 diabetes from the Middle East and Morocco
par: Shihabi AR, et autres
Publié: (2013)